Open AccessEVALUATION OF HUMAN IMMUNOGLOBULIN EFFECTIVENESS IN PATIENTS WITH SENSORYMOTOR POLYNEUROPATHY ASSOCIATED WITH MONOCLONAL GAMMAPATHY OF UNDETERMINED SIGNIFICANCE
Author(s) -
А. А. Яковлев,
Р. А. Гапешин,
А. Г. Смочилин,
М. В. Яковлева
Publication year - 2018
Publication title -
arhivʺ vnutrennej mediciny
Language(s) - English
Resource type - Journals
eISSN - 2411-6564
pISSN - 2226-6704
DOI - 10.20514/2226-6704-2018-8-4-278-284
Subject(s) - polyneuropathy , medicine , neuropathic pain , ataxia , monoclonal gammopathy of undetermined significance , dermatology , chronic inflammatory demyelinating polyneuropathy , monoclonal , antibody , anesthesia , immunology , monoclonal antibody , psychiatry
. A number of paraproteinemic polyneuropathy is directly linked to the monoclonal gammapathy of undetermined significance (MGUS). One of the first manifestations of MGUS in addition to the secretion of monoclonal immunoglobulin, and long before the manifestation of malignancy is polyneuropathy. Materials and Methods . Were examined in 16 patients with polyneuropathy associated with MGUS in age from 53 to 78 years. Patients underwent a course of infusion therapy with human immunoglobulin in the dose of 0.4 g/kg for 5 days. Results . After treatment revealed a reduction of the manifestations of the sensory component of the neuropathy, neuropathic pain and sensitive ataxia that was confirmed by electromyographic data of stabilography, and a rating on a scale Lovett, the scale of neuropathy disability score, the questionnaire «Pain detect». The motor component of polyneuropathy had more persistent symptoms. Conclusion . Treatment with human immunoglobulin is effective in reduction of neuropathic pain and sensory ataxia and in increase of superficial and deep sensation, while the motor component of polyneuropathy had more persistent symptoms.